TOULOUSE and ARCHAMPS,
France, March 27, 2017 /PRNewswire/ --
Dr. Philippe Lluel from
Urosphere, a company specialized in preclinical pharmacology of
urogenital tract, presented on behalf of all investigators two
scientific posters at the prestigious congress of the European
Association of Urology (EAU) in London, showing for the first time data on the
effects of Litoxetine on the urogenital system.
To view the Multimedia News Release, please click:
https://www.multivu.com/players/uk/8069851-ixaltis-data-litoxetine-eau/
A poster with oral communication took place on Friday, March 24th: "Effects of Litoxetine on
urethral pressure and detrusor overactivity in anesthetized female
rats."
The results of this study show that Litoxetine increases
activity of the urethral sphincter and reduces the overactivity of
the bladder, thus suggesting that it may play a beneficial role in
the treatment of mixed urinary incontinence.
A second abstract was presented on Saturday, March 25th: "Effects of Litoxetine on
acetic acid-induced detrusor overactivity and anal sphincter
functions in rabbits: Comparison with duloxetine".
This study in rabbits confirmed that Litoxetine is active on
both bladder hyperactivity and sphincter contraction, with
magnitude of effect similar to duloxetine.
The data presented give similar and complementary results, on
two different models, supporting the preclinical proof of concept
for this drug candidate as a new treatment for mixed urinary
incontinence.
IXALTIS is start-up company specialized in
genitourinary and renal diseases. It has acquired from Sanofi the
rights to three molecules, including Litoxetine IXA-001, and
completed the round A of financing in 2016.
Litoxetine is a highly selective serotonin (5-HT) reuptake
inhibitor and a multifunctional serotonin agonist-antagonist (MSAA)
under development for mixed urinary incontinence. A phase 2 dose
finding study is ongoing.
Mixed Urinary Incontinence (MUI) is a seriously debilitating
disease that affects about 400 million people worldwide and up to
50% of women over 50 years of age: no medical treatment is
currently approved for this disease.
More information and whole abstracts available in the
latest news section: http://www.ixaltis.com
(Photo:
http://mma.prnewswire.com/media/467980/Professor_Francois_Haab.jpg
)
Video:
https://www.multivu.com/players/uk/8069851-ixaltis-data-litoxetine-eau/